PitchSend

argenx SE Investor Day Presentation Deck

ARGX-117 MAD: Consistent Activity Mean ARGX117 Concentration µg/ml (log scale) 1E7 1 E6- 1E5- 1E4 0 argenx 7 Pharmacokinetics 14 Conclusions 21 Days 28 ● ● 35 42 49 Mean Free C2 µg/ml(log scale) 100 10- 0.1- 0.01- 0 7 14 21 Free C2 levels 28 35 42 49 Days 56 63 Placebo IV/SC on days 1, 8, 15, 22, and/or 29 60, 10, 10 mg/kg ARGX-117 IV on days 1, 8, and 22 10, 50, 20 mg/kg ARGX-117 IV on days 1, 8, and 22 10 mg/kg ARGX-117 IV on days 1, 8, 15, and 22 70 77 Induction dose followed by maintenance dosing concept established Resulting robust PK/PD model informing dosing strategy for Phase 2 studies 1.0 μg/ml T 84 0.2 µg/ml 91 98 59

View entire presentation